Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

3. Notes

16. Other income/expenses

16. Other income/expenses

Total other income/expenses amounted to an expense of € 102 million (2019: income of € 1 million) and is comprised of the following items:

  • Gain on disposal: € 53 million in 2020. € 16 million is related to the divestment of Niferex® (iron supplement) franchise in China (€ 41 million in 2019 related to the sale of Innere Medizin and non-core Established Brand products) and € 37 million related to the sale of Alprostadil in Germany.

  • Other expenses: € 155 million in 2020, related mainly to the Ra Pharma acquisition fees (€ 95 million), the Distilbène provision and intellectual property fees (2019: € 59 million and mainly relate to intellectual property fees and Distilbène provision).